| Wissenschaftl. Titel | A Phase 3, Open-Label, Randomized, Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) |
| Erkrankung |
Gyn:
Mamma-Ca:
Zweitlinie oder später
|
| Kurzprotokoll | Kurzprotokoll |
| Links | Weiterführende Informationen (MZ) |
erstellt 13.02.2024 Data entry III CCP
geändert 13.02.2024 Data entry III CCP